Abstract:
OBJECTIVE:To understand treatment preferences of people with migraine and the relative importance of improvements in efficacy and avoiding adverse events (AEs), such as cognition problems or weight gain. BACKGROUND:Current preventive migraine medicines are associated with poor adherence and tolerability. There is an unmet need for effective migraine-specific preventive treatments with fewer AEs. METHODS:In a web-based discrete-choice experiment survey, respondents who self-reported having ≥6 migraine days/month were offered choices between pairs of hypothetical preventive migraine medicines. Six attributes, each with 3 levels, defined the medicines: reduction in headache days per month (10%, 25%, or 50%), frequency of limitations with physical activities (none, 1-category improvement, or 2-category improvement), cognition problems (no problems, thinking problems, or memory problems), weight gain (none, 5% body weight gain, or 10% body weight gain), how the medicine is taken (daily oral pill, once-monthly injection, or twice-monthly injection), and monthly out-of-pocket cost ($5, $60, or $175). The attributes and levels were informed by clinician input, the clinical literature, and 2 focus groups. An experimental design was used to create the pairs of hypothetical medicines for the discrete-choice experiment questions. Random-parameters logit was used to estimate the relative importance of the medicine attributes, and the results were used to predict the percentage of respondents who would select one medicine profile over another and to calculate willingness to pay for changes in attribute levels. RESULTS:The sample included 300 respondents; 72% indicated that migraines make physical activities difficult all or most of the time, and 81% had taken a prescription medicine to prevent migraine in the last 6 months. Respondents reported having, on average, approximately 16 headache days per month. Among noncost attributes, respondents valued a change from a 10% reduction in migraine days to a 50% reduction more highly than avoiding the worst levels of AEs, but were willing to trade off efficacy for less-severe AEs. Avoiding memory problems was more important than avoiding thinking problems. Avoiding a 10% weight gain was more important than avoiding thinking and memory problems. Respondents preferred a once-monthly injection or daily pill to twice-monthly injection. Respondents, on average, were willing to pay $84 (95% confidence interval [CI], $64-$103) per month to avoid a 10% weight gain, $59 (95% CI, $42-$76) per month to avoid memory problems, $35 (95% CI, $20-$51) per month to avoid a 5% weight gain, and $32 (95% CI, $18-$46) per month to avoid thinking problems. CONCLUSIONS:A preventive migraine medicine with improved efficacy and AE profile and a favorable mode of administration would be valuable to migraine sufferers. Patients may be willing to trade off efficacy for better AE profiles. Clinicians should work with patients to select treatments that meet each patient's needs.
journal_name
Headachejournal_title
Headacheauthors
Mansfield C,Gebben DJ,Sutphin J,Tepper SJ,Schwedt TJ,Sapra S,Shah Ndoi
10.1111/head.13498subject
Has Abstractpub_date
2019-05-01 00:00:00pages
715-726issue
5eissn
0017-8748issn
1526-4610journal_volume
59pub_type
杂志文章相关文献
HEADACHE文献大全abstract:BACKGROUND:Borderline personality disorder (BPD) may be disproportionately common in the migraine patient population, but specific migraine features in the BPD subgroup remain incompletely characterized. PURPOSE:To define more clearly the clinical characteristics of migraine patients with BPD, to evaluate their clinic...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/j.1526-4610.2007.00649.x
更新日期:2007-01-01 00:00:00
abstract::Chronic drug exposure can induce a significant change in neurotransmitter receptor systems and is possibly involved in the pathogenesis of drug-induced neurological disorders. Abuse of analgesics is known to induce deterioration in headache status in patients with primary headaches, especially migraine. To assess the ...
journal_title:Headache
pub_type: 杂志文章
doi:10.1046/j.1526-4610.1998.3807534.x
更新日期:1998-07-01 00:00:00
abstract::Genetic mutations of sporadic hemiplegic migraine (SHM) are mostly unknown. SHM pathophysiology relies on cortical spreading depression (CSD), which might be responsible for ischemic brain infarction. Cystic fibrosis (CF) is caused by a monogenic mutation of the chlorine transmembrane conductance regulator (CFTR), pos...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/head.13472
更新日期:2019-02-01 00:00:00
abstract:OBJECTIVE:To explore the effects of olmesartan on frequency and severity of migraine attacks in patients with comorbid hypertension and prehypertension. BACKGROUND:A randomized, double-blind, placebo-controlled, crossover study with a total of 60 patients has demonstrated the efficacy and safety of the angiotensin II ...
journal_title:Headache
pub_type: 杂志文章,随机对照试验
doi:10.1111/j.1526-4610.2006.00382.x
更新日期:2006-03-01 00:00:00
abstract::Central excitatory circuits could be involved in the pathophysiology of pain; particularly, the genesis of chronic pain. The "second pain" is the sensation that follows the initial pain after an appropriate nociceptive stimulus. The second pain is amplified by repeating the stimulus after brief intervals (temporal sum...
journal_title:Headache
pub_type: 杂志文章
doi:10.1046/j.1526-4610.1997.3708486.x
更新日期:1997-09-01 00:00:00
abstract:OBJECTIVE:To evaluate the relationships among modifiable psychological factors and chronic migraine and severe migraine-related disability in a clinic-based sample of persons with migraine. BACKGROUND:Evidence evaluating relationships between modifiable psychological factors and chronic migraine and severe migraine-re...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/head.13021
更新日期:2017-04-01 00:00:00
abstract::Flunarizine is a non-selective calcium antagonist. It distributes preferentially in the adipose tissue and passes the blood brain barrier. Numerous controlled clinical studies have established that flunarizine is efficacious in migraine prophylaxis, including double-blind studies in which the drug was compared with pl...
journal_title:Headache
pub_type: 临床试验,杂志文章,随机对照试验,评审
doi:10.1111/j.1526-4610.1991.hed3106388.x
更新日期:1991-06-01 00:00:00
abstract:BACKGROUND:Recent research has shown that affective changes associated with the menstrual cycle may follow diverse patterns, including a classic premenstrual syndrome pattern, as well as the mirror opposite pattern, referred to as a mid-cycle pattern. OBJECTIVE:Test for the presence of a mid-cycle pattern of headaches...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/head.12082
更新日期:2013-06-01 00:00:00
abstract::A 72 year old woman with attacks of severe lancinating pain in the right frontotemporal region of her face had, on CT scan of the skull base, fibrous dysplasia of the right sphenoid bone, involving the areas traversed by the trigeminal nerve. Her pain ceased following treatment with methysergide. In patients with hemi...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/j.1526-4610.1990.hed3005277.x
更新日期:1990-04-01 00:00:00
abstract:OBJECTIVES:To determine the 1-year prevalence of headache and clinical characteristics of primary headaches among school children in South Korea. BACKGROUND:Many population-based studies have estimated the 1-year prevalence of headache, migraine, and tension-type headache (TTH). The results of those studies vary in te...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/j.1526-4610.2011.02001.x
更新日期:2012-04-01 00:00:00
abstract::Calcitonin-gene-related peptide (CGRP), a neuropeptide broadly distributed in neuronal and non-neuronal regions throughout the body, plays a fundamental role in migraine and cluster headache (CH) pathophysiology. CGRP functional blockade alleviates neurogenic inflammation and reduces pain pathway sensitization. Two ty...
journal_title:Headache
pub_type: 杂志文章,评审
doi:10.1111/head.13583
更新日期:2019-07-01 00:00:00
abstract::Patients suffering from cervicogenic headache (CeH) are commonly treated with spinal manipulative therapy. We have analyzed the quality and the outcomes of published, randomized, controlled trials assessing the effectiveness of spinal manipulation in CeH. Among 121 relevant articles, only two met all the inclusion cri...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/j.1526-4610.2005.00253_1.x
更新日期:2005-10-01 00:00:00
abstract::The treatment of migraine was transformed in 1992 with the introduction of the first triptan-based therapy, subcutaneous (SC) sumatriptan. SC sumatriptan has high efficacy and a rapid onset of action compared with other available triptans and formulations presumably because of its short Tmax, high Cmax, and avoidance ...
journal_title:Headache
pub_type: 杂志文章,评审
doi:10.1111/head.12183
更新日期:2013-09-01 00:00:00
abstract:OBJECTIVES:To estimate the 1-year prevalence of headache, its repercussion and its association with the academic performance of university students. METHODS:Cross-sectional study. Three hundred eighty students were randomly selected out of the 1718, 90.5% of them were interviewed. A semi-structured interview, the Head...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/j.1526-4610.2011.02012.x
更新日期:2011-11-01 00:00:00
abstract::Verapamil is used mainly in cardiovascular diseases. High-dose verapamil (360-720 mg) is, however, currently the mainstay in the prophylactic treatment of cluster headache. The oral pharmacokinetics are variable. The pharmacodynamic effect of verapamil, the effect on blood pressure, also varies considerably among subj...
journal_title:Headache
pub_type: 杂志文章,评审
doi:10.1111/j.1526-4610.2008.01298.x
更新日期:2009-01-01 00:00:00
abstract::Two adults presented with new-onset migrainous-type visual disturbances and had angiographically demonstrated filling defects near the torcular Herophili. Neither patient had a visual field deficit nor cerebral computed tomography evidence of an occipital infarction. The association of migraine-like visual phenomena w...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/j.1526-4610.1989.hed2902082.x
更新日期:1989-02-01 00:00:00
abstract::The symptoms of migraine are non-specific and can be present in many other primary and secondary headache disorders, which are reviewed. Even experienced headache specialists may be challenged at times when diagnosing what appears to be first or worst, new type, migraine status, and chronic migraine. ...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/head.12518
更新日期:2015-02-01 00:00:00
abstract:OBJECTIVE:To determine the pharmacological profile of frovatriptan. BACKGROUND:Frovatriptan is a new 5-HT(1B/1D) agonist developed for the treatment of migraine. METHODS:Pharmacological studies were performed using in vitro and in vivo techniques. RESULTS:Radioligand-binding studies showed that frovatriptan has a hi...
journal_title:Headache
pub_type: 杂志文章
doi:10.1046/j.1526-4610.42.s2.2.x
更新日期:2002-04-01 00:00:00
abstract::In a questionnaire survey we determined the prevalence of problems with reading, at present as well as in the past, in adult chronic headache sufferers as compared with age- and sex-matched controls. The reading problems inquired about were those with reading in general, reading quickly, prolonged reading and reading ...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/j.1526-4610.1991.hed3104244.x
更新日期:1991-04-01 00:00:00
abstract:AIMS:To assess the importance of service demographic, mental disorders, and deployment factors on headache severity and prevalence, and to assess the impact of headache on functional impairment. BACKGROUND:There is no information on prevalence and risk factors of headache in the UK military. Recent US reports suggest ...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/head.12101
更新日期:2013-05-01 00:00:00
abstract::Migraine is a chronic recurrent disorder with episodic manifestations that is progressive in some individuals. Migraine progresses clinically, physiologically, and anatomically. Progression may be a consequence of the mechanisms that generate the migraine attacks (eg, cortical spreading depression) or it may be a func...
journal_title:Headache
pub_type: 杂志文章,评审
doi:10.1111/j.1526-4610.2007.00969.x
更新日期:2008-01-01 00:00:00
abstract:BACKGROUND:Though triptans are considered the standard of acute therapy for migraine attacks with headache-related disability, they are used by the minority of potentially eligible persons. Understanding the socio-demographic and headache features that predict triptan use may help to clarify barriers to optimal treatme...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/j.1526-4610.2011.02032.x
更新日期:2012-02-01 00:00:00
abstract:OBJECTIVE:Previous attempts to develop a pragmatic human model for testing new anti-migraine drugs, have failed. Calcitonin gene-related peptide (CGRP) induces a mild headache in healthy volunteers and migraine-like headache in migraine patients. The induced headache must respond to already established migraine treatme...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/head.13747
更新日期:2020-04-01 00:00:00
abstract:OBJECTIVE:We aimed to investigate (1) to which extent headache diary variables correlate among each other; (2) to which extent they correlate with generic measures of quality of life and disability; (3) and whether correlations vary over time. METHODS:We performed a secondary analysis of data from 301 patients sufferi...
journal_title:Headache
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1111/j.1526-4610.2009.01434.x
更新日期:2009-06-01 00:00:00
abstract:OBJECTIVES:The aim of our study was to investigate the prevalence of sleep disorders in chronic headache patients and to evaluate the role of psychiatric comorbidity in the association between chronic headache and sleep complaints. BACKGROUND:The prevalence of sleep disorders in chronic headache has been seldom invest...
journal_title:Headache
pub_type: 杂志文章,评审
doi:10.1111/j.1526-4610.2010.01711.x
更新日期:2010-10-01 00:00:00
abstract:OBJECTIVE:To examine the efficacy of L-kynurenine and a novel kynurenic acid derivative on the nitroglycerin-induced calmodulin-dependent protein kinase II alpha (CamKIIalpha) and calcitonin gene-related peptide (CGRP) expression changes in the rat caudal trigeminal nucleus. BACKGROUND:Systemic administration of the n...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/j.1526-4610.2009.01574.x
更新日期:2010-05-01 00:00:00
abstract:OBJECTIVES:To provide a guide to the use and limitations of continuous opioid therapy (COT, or daily scheduled opioids) for refractory daily headache, based on the best available evidence and expert clinical experience. BACKGROUND:There has been a dramatic increase in opioid administration over the past 25 years, with...
journal_title:Headache
pub_type: 杂志文章,实务指引,评审
doi:10.1111/j.1526-4610.2010.01733.x
更新日期:2010-07-01 00:00:00
abstract:OBJECTIVE:To evaluate the effectiveness of rizatriptan for acute migraine treatment and patient satisfaction with the drug in usual clinical practice settings. BACKGROUND:Although rizatriptan has been shown to effectively relieve migraine symptoms in clinical trials, we wished to assess its utility in typical patient ...
journal_title:Headache
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1046/j.1526-4610.2003.03045.x
更新日期:2003-03-01 00:00:00
abstract:OBJECTIVES:The purpose of this study was to evaluate the course of headache in patients with moderate-to-severe headache due to aneurysmal subarachnoid hemorrhage (aSAH) and to identify its predisposing factors. BACKGROUND:Little is known about the long-term course of headache in patients with aSAH. METHODS:Since Sep...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/head.12612
更新日期:2015-07-01 00:00:00
abstract::Discrimination toward people living with migraine and other headache disorders is widespread and socially accepted. Stigma toward these diseases is both a manifestation of these discriminatory attitudes and a sustainer of them. For those living with migraine and headache disorders, stigma limits the full expression of...
journal_title:Headache
pub_type: 杂志文章
doi:10.1111/head.13913
更新日期:2020-10-01 00:00:00